Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
PGHLNSEProcter & Gamble Health Limited· Pharmaceuticals & BiotechnologyHighNegative
Announced Tue, 16 Sept, 2025 · 17:07 IST

CFO Lokesh Chandak resigns; Shashank Srowthy appointed

Cfo ResignedKmp ResignedManagement Changes View source PDFExplain this filing

PGHL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.5%Reaction day
₹6360.00
prior close
₹6399.00
announcement price
After-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.6%-1.1% vs market
Pharmaceuticals peers, median of 154sector+0.1%-0.6% vs sector

On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.8
10m
-0.4
15m
+0.0
30m
-0.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.5+0.6-1.1+0.1-0.6
Next day
-1.3+0.4-1.7+0.3-1.6
2d
+0.3+0.8-0.4+0.2+0.2
3d
-1.7+0.0-1.7-0.6-1.1
4d
-1.0-0.3-0.7-0.9-0.1
5d
-1.3-0.6-0.7-1.1-0.3
1w
-1.1-3.8+2.7-4.0+2.9
15d
-4.1-2.9-1.1-3.5-0.6
1m
-1.8-2.9+1.1-4.1+2.3
2m
-6.9-1.5-5.4-4.9-2.0
3m
-9.9-8.1-1.9-8.0-1.9
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mr. Lokesh Chandak resigned as Director and Chief Financial Officer effective September 30, 2025, to take a senior finance role within P&G. The board appointed Mr. Shashank Srowthy as CFO and Additional Executive Director from October 1, 2025. Srowthy has 14 years of P&G finance experience, and his directorship requires government and shareholder approvals.

Likely market impact

The planned internal succession reduces management disruption, but investors should monitor execution and completion of Srowthy's directorship approvals.